Microbiology Conferences 2018 | International conferences | medical | clinical microbiology | microbiology

Theme: Get updates on all the recent advances in microbiology

Clinical Microbiology 2018

Clinical Microbiology 2018

After the success of Clinical Microbiology 2017 hosted by the Conference Series at Bangkok, Thailand during July 03-04, 2017, with the theme “To magnify the knowledge in the field of clinical microbiology”, ConferenceSeries Ltd is glad to announce the 2^nd International Conference on Medical and Clinical Microbiology during July 16th-17th, 2018 at Melbourne, Australia. ConferenceSeries Ltd Organises 1000 International Conferences every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 500+ Open access journals which contains over 50000 eminent personalities, 50,000 reputed scientists as editorial board members and 5 million readers.

This exciting event is managed in such a way to provide an exclusive platform for educators, new researchers, and learners to present and discuss all the most recent innovations, possibilities, and concerns adopted in the field of Clinical Microbiology. You will have an opportunity to meet leading global microbiology experts at the “2^nd International Conference on Medical and Clinical Microbiology”. which will be held during July 16th-17th, 2018 in Melbourne, Australia. It will focus on the most up-to-date research related to the laboratory diagnosis of human infections and the role of the laboratory in both the management of infectious diseases and the elucidation of the epidemiology of infections, the latest developments in clinical microbiology and immunology, providing the current state of knowledge in the field, as well as balanced, thought-provoking perspectives on controversial issues.

This event will comprise an informative and exciting conference program including leading keynote speakers, poster presenters, session speakers who will be presenting their research on the topics related to Clinical Microbiology.

Clinical Microbiology is a science related discipline that deals with use and the application of microorganisms for human benefit. It is a branch of medical science concerned with the prevention, diagnosis and treatment of infectious diseases. Moreover, this field of science is concerned about various clinical applications of microbes for the improvement of health.

Therefore, to acquire all this information and knowledge we heartedly invite you to join us at the 2^nd International Conference on Medical and Clinical Microbiology, where you will be sure to have a wonderful experience with experts from around the world.

Why to attend?

Best location to speed up your route in this field into every territory in the World.
89% our conference attendees are the key contact in their labs purchasing decisions.
Our exhibitor booths have higher visiting percentage. Up to 4-5 times by 80% of the attendees during the conference.
Best platform to develop and progress new partnership & collaborations.
Past exhibitor’s feedback reveals ample of enquiries perceived from the conference attendees.
Network development with both Academia and Business.

Target Audience

We invite experts in the field of clinical microbiology who have vast knowledge and experience in this field including bacteriology, virology, molecular microbiology, infection and quality control, exercise physiology, yoga, veterinary microbiology and delegates from industries focusing on microbiology, molecular genomics and industrialist involved in biomedical research as well.

Clinical Microbiology-2018 invites pioneer speakers, students and exhibitors from across the world to attend and register for the “the 2^nd International Conference on Medical and Clinical Microbiology” which is going to be venerated from July 16th-17th, 2018 at Melbourne, Australia.

We invite you to accompany us at the 2^nd Clinical Microbiology-2018, where you are assured to have a substantially worthwhile experience with global scholars.

Track 1: Microbial Biofilms:

A biofilm is a combination of microbial communities enclosed by a matrix of extracellular polymeric substance (EPS) and divided by a network of open water channels. These microbial communities stick to surfaces, manmade and natural such as metals and teeth, typically at any liquid-solid interface. A Biofilm extracellular compound substance, that's additionally same as slime (although not everything described as slime is also a biofilm), is also a polymeric conglomeration sometimes composed of polymer, proteins, and polysaccharides.

8^th Global Summit on Microbiology & Infectious Diseases February 22-23, 2018 Paris, France; 16^th International Pharmaceutical Microbiology and Biotechnology Conference May 21-23, 2018 Vienna, Austria; 8th Annual Congress on Clinical Microbiology December 05-06, 2018 Vancouver, Canada; 11th World Congress on Virology and Infectious Diseases May 17-18, 2018 Tokyo, Japan; 3rd International Conference on Applied Microbiology and Beneficial Microbes June 6-7, 2018 Osaka, Japan; 2nd International Conference on Microbial Pathogenesis & Infectious Diseases June 25-26, 2018 Vancouver, Canada; 11th World Microbiology & Immunology Congress June 28-29, 2018 Amsterdam, Netherlands; Microbial Ecology & Eco Systems July 11-12, 2018 Toronto, Ontario, Canada

Track 2: Immunity and Vaccination:

The capacity of an organism to resist disease, either through the activities of dedicated blood cells or antibodies produced by them in response to natural exposure or inoculation (active immunity). A vaccine is a product that produces immunity from a disease and can be directed through needle injections, by mouth, or by aerosol. A vaccination is the injection of a killed or weakened organism that produces immunity in the body against that organism. Vaccination is one of the efficient processes in bar of numberless diseases; immunity that’s provided because of vaccination is agile to wipe out the various infections and diseases whereas weakening the results of the many various diseases particularly within the developing countries. There are vaccines that are administered entirely when the patient has contracted an illness. The intent of such immunizations is to cause an immediate reaction with weakened side-effects.

8^th Global Summit on Microbiology & Infectious Diseases February 22-23, 2018 Paris, France; Global Experts Meeting On Diabetes, Hypertension & Metabolic Syndrome July 30-31, 2018 Melbourne, Australia; 16^th International Pharmaceutical Microbiology and Biotechnology Conference May 21-23, 2018 Vienna, Austria; 8th Annual Congress on Clinical Microbiology December 05-06, 2018 Vancouver, Canada; 11th World Congress on Virology and Infectious Diseases May 17-18, 2018 Tokyo, Japan; 3rd International Conference on Applied Microbiology and Beneficial Microbes June 6-7, 2018 Osaka, Japan; 2nd International Conference on Microbial Pathogenesis & Infectious Diseases June 25-26, 2018 Vancouver, Canada; 11th World Microbiology & Immunology Congress June 28-29, 2018 Amsterdam, Netherlands; Microbial Ecology & Eco Systems July 11-12, 2018 Toronto, Ontario, Canada

Track 3: Microbial Pathogenesis:

Microbial Pathogenesis is the study of the molecular mechanisms used by microbes to cause disease in humans and animals. Bacterial, fungal, protozoan and viral pathogens have advanced a wide variety of tools to establish themselves in the host and gain nutrients, which also causes damage and disease. Often, a probable aetiology is known by medicine clarifications before a pathological link may be drawn between the cause. The pathological perspective is also directly combined into associate degree drugs approach within the knowledge based field of molecular pathological medicine. Molecular pathological drugs will simplify to assess pathologic process and relation by linking a possible etiologic issue to molecular pathologic signs of an illness. Thus, the molecular pathological epidemiology paradigm will develop in the realm of causative reasoning.

Track 4: Nosocomial Infections:

A nosocomial infection is contracted because of an infection or toxin that exists in a certain place, such as a hospital. People now use nosocomial infections interchangeably with the terms health-care associated infections (HAIs) and hospital-acquired infections. For a HAI, the infection must not be existing before someone has been under medical care, it is unfolded within the hospital setting, home setting, rehabilitation facility, clinical setting, or alternative clinical settings. Bacteria, fungus, and viruses can cause HAIs. Bacteria alone cause about 90 percent of these cases. Many people have compromised immune systems during their hospital stay, so they’re furthermore prone to likely contract an infection. They spread mainly through person-to-person contact. This includes unclean hands, and medical instruments such as catheters, respiratory machines, and other hospital tools. HAI cases also increase when there’s unnecessary and improper use of antibiotics. This can lead to bacteria that are unaffected to multiple antibiotics.

Track 5: Infection Control and Hospital Epidemiology:

Infection control is the discipline concerned with preventing nosocomial or healthcare-associated infection, a practical (rather than academic) sub-discipline of epidemiology. It is a vital, though often under recognized and under supported part of the organization of health care. Infection control and hospital epidemiology are like public health practice, practiced within the boundaries of a particular health-care delivery system rather than directed at the entire society. Anti-infective agents include antibiotics, antibacterial, antifungals, antivirals and antiprotozoal. These are promptly accessible to infections. Infection control and Hospital epidemiology are related to the general public health practice. Infection management contains elements relevant to the spreading of infections; either within the hospitals or alternative aid centres, as well as difficulty via hand hygiene, cleansing or disinfection or sanitization, vaccines or surveillance and probe of infections in a health-care domain. Sterilization kills all microorganisms. It is on this basis that the common title being adopted among health care is “prevention and control”.

Track 6: Microbial Infections:

Infection is the invasion of an organism's body tissues by disease-causing agents, their growth, and the reaction of host tissues to these organisms and the toxins they produce. The basic lexicon of infectious diseases includes the terms exposure, infection due to infectious agents including viruses, viroid, prions, bacteria, nematodes such as parasitic roundworms and pinworms, arthropods such as ticks, mites, fleas, and lice, fungi such as ringworm, and other macro parasites such as tapeworms and other helminths.

Infectious disease, also known as contagious disease or communicable disease, is illness resulting from an infection. Another issue to extensive use of the lexicon is that microorganism factors unit of measurement usually in command of the pathological process. This states that the host plays in microbial pathologic process to associate exception that leads to the need for qualification and modification of the language of infectious diseases. Recently, we tend to project the "damage-response basis" to include the contributions of each the host and the organism in microorganism pathological process in a synthesis whereby host was used because of the common divisor to explain the end results of the host-microbe relation.

Track 7: Disease, Diagnosis and Prevention:

A disease is an abnormal condition, a disorder of a structure or function, that affects part or the organism entirely. The study of disease is called pathology which includes the study of cause of the disease. Disease is often construed as a medical condition associated with specific symptoms and signs. Detection of a specific agent for an infection or a health problem is done in clinical presentation. Diagnostic biological science laboratory plays a vital role in diagnosing with uninflected of microbiological culture being the primitive approach for isolation of the conducive organism within the laboratory. It may be caused by external factors such as pathogens, or it may be caused by internal dysfunctions particularly of the immune system such as an immunodeficiency, or a hypersensitivity including allergies and autoimmunity.

Track 8: Antimicrobials and Chemotherapy:

An antimicrobial can be described as an agent that kills microorganisms or stops their growth. Antimicrobial medicines can be assembled according to the microorganisms they principally act against. Antibiotics are used against bacteria and antifungals are used against fungi. Antimicrobial chemotherapy implements the clinical use of antimicrobial agents in treating infectious disease. The positive conclusion of this antimicrobial medical aid depends on many factors like site of infection, host defence mechanisms and pharmacokinetic and pharmacodynamics activity of the antibacterial drug agent. They can also be categorised according to their function. Agents that kill microbes are called microbicidal, while those that merely inhibit their growth are called biostatic. The use of antimicrobial medicines to treat infection is known as antimicrobial chemotherapy, while the use of antimicrobial medicines to prevent infection is known as antimicrobial prophylaxis. Antimicrobial agents that treat microorganism infections are a unit such as medicine therapy, equally for fungal, microorganism and protozoan infections are such as antifungal, antiviral and antiprotozoal therapy.

Track 9: Antimicrobial Resistance:

Antimicrobial resistance occurs when microorganisms (such as bacteria, fungi, viruses, and parasites) transform when they are exposed to antimicrobial drugs (such as antibiotics, antifungals, antivirals, antimalarial, and anthelmintic). Antimicrobial resistance (AMR) is, once a microbe evolves to become additional or immune to antimicrobials that antecedent may treat it. Microorganisms that develop antimicrobial resistance are sometimes referred to as “superbugs”. Resistance can appear spontaneously because of random mutations; or additional usually following gradual build up over time, and since of misuse of antibiotics or antimicrobials. Resistant microbes are progressively tough to treat, requiring alternative medications or higher doses—which could also be more expensive or more toxic. Microbes resistant to multiple antimicrobials are known as multidrug resistant (MDR); or generally superbugs. Antimicrobial resistance is on the increase with various deaths every year. A few infections are now completely untreatable due to resistance.

Track 10: Microbial Biochemistry:

Microbial biochemistry covers the principles and importance of microbes, their growth and their effects on our surroundings at large and on human health specifically. Microbial biochemistry allowed the formulation of concepts that turned out to be significant in the study of higher organisms. The outline of various layers that enclose the bacterial protoplasm, and their role in getting nutrients from the surface media through totally different permeability mechanism are represented. Fundamentals of the mechanisms are how cells get the energy necessary for their growth, mechanisms like, glycolysis, the pentose phosphate pathway, etc.

Track 11: Health Science:

Health science contains of applied sciences, biomedicine, and encompasses a variety of sub-disciplines, all of which relate to the application of science to health. Both traditional, Western and alternative medicine can be considered health sciences as humans have always needed to deal with illness, it could be said that health science has existed for as long as humans have. Diagnostics methods like aboriginal physical examination, past anamnesis and current medical imaging cover the rudiments of 1st diagnosis of the illness that follow expedited laboratory identification of patient for any serological infectious agents. The field includes the study of medicine, nutrition and other health-related issues and the affect they may have on both humans and animals.

Track 12: Host Pathogens Interaction:

Host pathogen interaction takes place between a pathogen and a host. Microbial pathogens, particularly those that have sustained a long-standing association with their hosts, have evolved extremely complex adaptations to secure their own replication and survival. Pathogens include bacteria, fungi and viruses. Each of these several types of organisms can then be further classified as a pathogen based on its mode of transmission. This includes the following: food borne, airborne, waterborne, blood borne, and vector-borne. Many pathogenic bacteria, such as Staphylococcus aureus and Clostridium botulinum are food borne pathogens that secrete toxins into the host to cause symptoms. HIV and Hepatitis B are viral infections caused by blood borne pathogens, and Aspergillus is the most common pathogenic fungi that secretes aflatoxin which acts as a carcinogen and contaminates many foods, especially those grown underground (nuts, potatoes, etc.). Microbes may be both hosts or pathogens and the studies of microorganism pathogenesis results in the identification of molecular variations between a pathogenic and a non-pathogenic microorganism.

Track 13: Medical Microbiology:

Medical microbiology is that the study of prevention, diagnosis and treatment of infectious diseases. Medical microbiology includes numerous applications of microbes for the improvement of health and hindrance of epidemics or natural event of diseases and illness. Four major types of microorganisms inflicting infectious disease are bacteria, fungi, parasites and viruses and also including an infectious protein called a prion. Elaborated identification techniques typically used in laboratories are microbial culture, microscopy, biochemical tests and polymerase chain reaction.

Importance and Scope

Clinical Microbiology-2018 is a premier forum to analyse recent innovations and challenges in the field of Clinical Microbiology. Clinical Microbiology-2018 welcomes students, speakers, presenters, and exhibitors from across the world to Melbourne, Australia on July 16th-17th, 2018.Clinical microbiology and infections are a risk and is considered a danger to most of laboratories or hospitals and they mostly deal with the prevention, diagnosis and treatment of pathogenic diseases caused by microorganisms. As microbes nearly affect all activities of our life like, food, clothing, shelter, health hygiene etc., microbiology has made vast progressive steps in all these fields in little less than a century to improve the quality of our life. It has become increasingly important to human society. It has emerged as one of the most important and vital branches of life sciences. Infectious diseases have almost been conquered by new drugs, quality of agricultural crops improved by using techniques of genetic engineering, new varieties of wines, liquors have been produced- all these are possible only because of microbiology. All these advancements will make us wonder how our life would have been without the knowledge of microbiology.

Medical microbiology can also be integrated into Clinical Microbiology as a science of studying various clinical applications of microbes for the enhancement of health and development of human life. Microbial diseases caused by pathogens may be exogenous or endogenous. In microbiology laboratory, cultures are the primary method used for isolating infectious diseases for study in the laboratory. Tissue or fluid samples are tested for the presence of a specific pathogen, which is determined by growth in a selective or differential medium.

Microbial diagnosis involves microbial culture, microscopy, biochemical tests and genotyping. Other less common techniques (such as X-rays, CAT scans, PET scans or NMR) are sometimes used to produce images of internal abnormalities resulting from the development of an infectious agent. Once an infectious disease has been diagnosed and identified, suitable treatment options must be evaluated by the physician and consulting medical microbiologists. Clinical Infectious diseases are treated with anti- bacterial (often called antibiotics) whereas fungal and viral infections are treated with antifungals and antivirals respectively. A broad class of drugs known as anti-parasitic are used to treat parasitic diseases. Clinical infections can be treated and these treatments can be developed from microbes, as demonstrated by Alexander Fleming's discovery of penicillin as well as the development of new antibiotics from the bacterial genus Streptomyces among many others.

Why Australia?

Melbourne is the coastal capital and most crowded city of the south-eastern Australian state of Victoria. It was changed into one of the world's biggest and wealthiest urban communities, amid Victorian Gold Rush in 1850. At the city's centre is the modern Federation Square development, with plazas, bars, and restaurants by the Yarra River. In the Southbank area, the Melbourne Arts Precinct is the site of Arts Centre Melbourne – a performing arts complex – and the National Gallery of Victoria, with Australian and indigenous art. Research facilities are located at key sites across Victoria, with more conducting research around the world. Renowned experts from every field can be found in labs, hospitals, affiliated research institutes and all across the wider community. Although there are a few research centers dedicated to clinical microbiology, at present it is fairly less due to the unobtainability of funds and lack of proper expertise. The Asia-Pacific region is expected to grow at a faster CAGR owing to presence of high unmet healthcare needs, research collaborations and increase in microbiology research funding in emerging economies such as Australia, China, India and other economies in the region. China is expected to surpass the United States. Due to the increasing economic conditions which will lead to more awareness, the market is set to grow rapidly in the coming years. Australia has been expected to project a high market growth in the coming years in the field of medical and clinical microbiology.

Conference Highlights

1. Microbial Biofilms

2. Immunity and Vaccination

3. Microbial Pathogenesis

4. Nosocomial Infections

5. Infection Control and Hospital Epidemiology

6. Microbial Infections

7. Disease, Diagnosis and Prevention

8. Antimicrobials and Chemotherapy

9. Antimicrobial Resistance

10. Microbial Biochemistry

11. Health Science

12. Host Pathogens Interaction

13. Medical Microbiology

Market value

The clinical microbiology market in Asia Pacific for medical microbiology testing technologies will exhibit the highest market growth at a CAGR of 7.3%. High conversion rate from traditional testing methods to new advanced testing technologies is the key factors projected to trigger the market growth in APAC. The Asia Pacific region is also expected to lead product development and adoption of newer technologies. Improving economic conditions leading to increased purchasing power, increasing awareness regarding the benefit of testing technologies, and the presence of a large pool of patients suffering from various chronic diseases, the market is expected to grow at a double-digit rate.

The Global Clinical Microbiology Market is projected to reach USD 5.77 Billion by 2021 from USD 3.35 billion in 2016, at a CAGR of 11.5%, during the duration 2016 to 2021. On the basis of product, the clinical microbiology market is categorized into gram strainers, bacterial colony counters, incubators, autoclave sterilizers, , anaerobic culture systems, microbial air samplers, petri dish fillers, blood culture systems, microbial culture systems which come under laboratory instruments and other laboratory instruments and such as microscopes, molecular diagnostic instruments, and mass spectrometers and reagents like pathogen specific kits and general reagents which are categorized as microbiology analyzers. The instruments sector is expected to account for the larger share of the global clinical microbiology market than the reagents sector in 2016. However, reagents sector is predicted to grow faster than the instruments sector, growing at a double-digit CAGR during 2016–2021. Growth in the reagents sector is largely driven by growing trend of reagent rental agreements (along with instrument sales) by prominent reagent manufacturers, raising private-public funding for researches on specific infectious diseases, increasing market obtainability of pathogen-specific kits across the globe, and growing demand for specific clinical microbiology reagents during widespread epidemic outbreaks.

Technological advancements, rising incidence of infectious diseases and growing outbreak of epidemics, growing healthcare expenditure across the world, and increasing funding, research grants, and public-private investments in the field of life science researches are recognized to be the key market drivers for the clinical microbiology industry. Furthermore, improving healthcare infrastructure across the emerging markets and growing market demand for advanced molecular diagnostic products which provide opportunities for players in the clinical microbiology market. Functioning barriers for diagnostic test usage and bundled sales by market giants across major markets are the major challenge limiting the growth of the global clinical microbiology market.

In 2016, North America and Europe are expected to be the developed markets for clinical microbiology products. However, emerging regions such as Asia-Pacific (including Japan, China, and India) are expected to become the new revenue-generating pockets in the clinical microbiology market in the next five years. The North American clinical microbiology market is expected to hold the largest share of the global clinical microbiology market in 2016. However, Asia-Pacific clinical microbiology market is likely projected to grow at the highest CAGR during the forecast period due to the growing number of hospitals and clinical diagnostic laboratories in India and China, expanding research capabilities for the development of innovative and affordable clinical microbiology testing procedures across India, China, and Japan, and increasing occurrences of infectious diseases.

Top players in the clinical microbiology market

1. bioMerieux S.A. (France)

2. Danaher Corporation (U.S.)

3. Becton, Dickinson and Company (U.S.)

4. Cepheid (U.S.)

5. Abbott Laboratories Inc. (U.S.)

6. Bio-Rad Laboratories Inc. (U.S.)

7. F. Hoffman-La Roche Ltd. (Switzerland)

8. Alere Inc. (U.S.)

9. Bruker Corporation (U.S.)

10. Hologic, Inc. (U.S.).

Growth rate for drug discovery technologies

The growth rate for drug discovery technologies reached nearly $39.9 billion and $46.8 billion throughout the years 2013 and 2014. However, this market is expected to grow at a compound annual growth rate (CAGR) of 11.3% to nearly $79.5 billion during the period of 2014-2019. Furthermore, this market is poised to grow at a CAGR of around 12.2% over the next decade and will reach approximately $160 billion by 2025.

The global systemic growth of antibiotics, its technologies and global market reached nearly $44.7 billion in 2020 from nearly $40.6 billion in 2015 at a compound annual growth rate (CAGR) of 2.0% from 2015 to 2020.

The Pharmacy Automation, Technologies and Global Markets, its global inpatient and outpatient market has grown to nearly $3.8 billion in 2016 from $3.5 billion in 2015. This market is projected to grow at a five-year compound annual growth rate (CAGR) of 7.9% from 2016 to 2021, increasing to $5.5 billion in 2021.

Global market in microbiology

The consumables, equipment and technology markets in the microbiology industry totalled nearly $7.7 billion in 2012. This total is expected to rise from $8.5 billion in 2013 to an exceptional rise of $11.4 billion in 2018, with a compound annual growth rate (CAGR) of 6.1% for the five-year period, 2013 to 2018.

The drug discovery market is generally broken down into seven segments:

1. High-throughput screening.

2. Bioanalytical instruments for drug discovery.

3. Cell-based assays for drug discovery.

4. Proteomics drug discovery.

5. Genomics drug discovery.

6. Bioinformatics as a platform for drug discovery.

7. And other (metabolomics-based technologies, combinatorial chemistry, systems biology, and nanotechnology products).

The High-throughput screening was projected to reach up to $11.5 billion in 2012 and should reach $20 billion in 2017, resulting in a CAGR of 11.7%.

The bioanalytical instruments for drug discovery segment was projected to reach a total of $10 billion in 2012 and should reach $15 billion in 2017, with a CAGR of 8.4%.

Cell-based assays for drug discovery was projected to be worth $7.5 billion in 2012 and should reach $15 billion in 2017, also increasing the CAGR by 14.9%.

Proteomics drug discovery was expected to total $5 billion in 2012 and should project an increase of $10 billion in 2017, also a CAGR of 14.9%.

Although having smaller projected total values, the remaining three segments which includes genomics drug discovery, bioinformatics as a platform for drug discovery, and other should reach a relatively high compound annual growth rates of 23.4%, 22.2%, and 16.5%, respectively.

Drug discovery is an intricate process and embodies a main component of the pharmaceutical industry. Today, development of new drugs can take up to 15 years with average spending of more than $1 billion. Most drug discovery today is based on target identification and further screening for drug candidates. However, the efficiency of this approach was found to be very low. To explain, in general, from thousands of compounds, only a few of the candidates are identified and are further developed as commercial drugs for market. Obviously, technology development plays an essential and vital part in accelerating this process and also in lowering its costs for consumption.

Despite of the many research and development (R&D) efforts, the pharmaceutical market today has shown low yield rate in the setting of new therapeutics on the market. Many marketed drugs today are going off patent, yet the number of new breakthrough medicines is not rising. Most of the industry insiders blame the economic downturn, rigid big pharmaceutical structures, and the latter’s present business models as the main reasons for the current situation, but it has been clear that the innovative technologies are essential for market development and are the driving force of this industry to produce breakthroughs in the research and development field.

This report provides understanding and helps to properly evaluate each segment in the drug discovery technology market.

Avail up to 15 CME Credits CPD Credits by CPD Standards Office

• UK IOCM Certification

• Networking with the experts and influencers is always a benefit

• Live Streaming of the conference Keynote sessions by world’s most eminent researchers

• Worldwide recognition through the speaker profile updated on Google

• Recognition of speaker’s work through the abstract page incorporated in Google our website

• Get updates about latest therapies, tools and techniques in your field from around the world under a single roof

• Top Industries Representation

• Thought provoking Symposia’s and Workshops

• Nominations for Best Poster Award

• Outstanding Young Researcher Award Group Registration benefits

• Group Registration benefits

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	July 16-17, 2018
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed
Poster Opportunity Closed	Click Here to View

Media Partners

Useful Links

Special Issues

All accepted abstracts will be published in respective Our International Journals.

Abstracts will be provided with Digital Object Identifier by

Testimonials

I enjoyed the meeting
Mervat Kassem, Alexandria University, Egypt

It was a real pleasure to participate in this scientific meeting
Anna Goc, Dr. Rath Research Institute BV, USA

Thank you so much for the opportunity of learning with all the colleagues I met there.
Ana MarÃa Arnaiz GarcÃa, University Hospital MarquÃ©s De Valdecilla, Spain

I learned a lot from your conference and love to chair or co- chair a session. I will help recruit speakers to the next meeting as an organizer member of the conference committee
Shabaan Abdallah University of Cincinnati, USA

This Conference was one of the best and even brilliant I have ever attended. There was very nice to have a mix between theory, basic science, sharing best practices and practical recommendations. The quality of the panels was outstanding, and I think you arranged a great cross-section of topics!
Sergey Suchkov I M Sechenov First Moscow State Medical University, Russia

It was a great pleasure for me to attend the conference. It was perfectly organized, I met many nice people and listen to many valuable talks.
Elzbieta Jarzebowska Warsaw University of Technology, Poland

2nd International Conference on Medical and Clinical Microbiology July 16-17, 2018 Melbourne,Australia

Recommended Global Microbiology Conferences

USA & Americas

Europe & Middle East

Asia Pacific

Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums Every year on Medical, Pharma, Engineering, Science, Technology and Business.

For more Conferences visit www.conferenceseries.com

Quick Links